Kalra Sanjay, Utz James P, Ryu Jay H
Division of Pulmonary and Critical Care Medicine and Internal Medicine, Mayo Clinic, Rochester, Minn. 55905, USA.
Mayo Clin Proc. 2003 Sep;78(9):1082-7. doi: 10.4065/78.9.1082.
To report on observations made in a group of patients with idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP) who were treated with interferon gamma-1b.
We reviewed the clinical records, radiological studies, and pulmonary function data of all patients treated with interferon gamma-1b between January 2000 and March 2002 at the Mayo Clinic in Rochester, Minn.
Twenty-one patients (mean age, 68 years; range, 52-80 years) were treated with interferon gamma-1b for a mean duration of 82 months (range, 3-21 months). All patients had been diagnosed previously as having IPF/UIP based on clinical, pulmonary function, and chest high-resolution computed tomographic scan criteria; 12 patients had also undergone video-assisted thoracoscopic surgical lung biopsy. Baseline pulmonary function data (mean +/- SEM percent predicted) were as follows: total lung capacity, 57.3 +/- 2.5; vital capacity, 55.0 +/- 3.3; diffusing capacity of lung for carbon monoxide, 39.7 +/- 2.8; and forced expiratory volume in 1 second, 58.1 +/- 3.6. Only 1 patient showed symptomatic and functional improvement, and 7 discontinued treatment because of a perceived lack of benefit. Eleven patients (52%) died after a mean of 6.4 months of treatment, and follow-up pulmonary function data suggested continued worsening in all but 1 patient.
These observations do not support the use of interferon gamma-lb therapy for patients with advanced IPF/UIP.
报告一组接受γ-1b干扰素治疗的特发性肺纤维化/普通型间质性肺炎（IPF/UIP）患者的观察结果。
我们回顾了2000年1月至2002年3月在明尼苏达州罗切斯特市梅奥诊所接受γ-1b干扰素治疗的所有患者的临床记录、放射学研究和肺功能数据。
21例患者（平均年龄68岁；范围52 - 80岁）接受了γ-1b干扰素治疗，平均疗程82个月（范围3 - 21个月）。所有患者此前均根据临床、肺功能和胸部高分辨率计算机断层扫描标准被诊断为IPF/UIP；12例患者还接受了电视辅助胸腔镜手术肺活检。基线肺功能数据（平均±标准误，预测值百分比）如下：肺总量，57.3±2.5；肺活量，55.0±3.3；肺一氧化碳弥散量，39.7±2.8；1秒用力呼气量，58.1±3.6。仅1例患者显示出症状和功能改善，7例因认为无益处而停止治疗。11例患者（52%）在平均治疗6.4个月后死亡，随访肺功能数据表明除1例患者外所有患者病情持续恶化。
这些观察结果不支持对晚期IPF/UIP患者使用γ-1b干扰素治疗。
